## Clinical Oversight Review Board (CORB) Criteria for Prescribing

## Golimumab IV (Simponi Aria)

Non-Formulary golimumab IV (Simponi Aria) requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-formulary golimumab IV (Simponi Aria) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a Rheumatologist
- Patient has a diagnosis of rheumatoid arthritis
- Patient has intolerance to, contraindication to, or failed treatment with the following: infliximab product and rituximab product

## -OR-

- Prescriber is a Rheumatologist
- Patient has a diagnosis of psoriatic arthritis
- Patient has intolerance to, contraindication to, or failed treatment with the following: infliximab product

## -OR-

- Prescriber is a Rheumatologist
- Patient has a diagnosis of spondyloarthropathy
- Patient has intolerance to, contraindication to, or failed treatment with the following: infliximab product

kp.org

Revised: 05/09/19 Effective: 06/06/19



All plans offered and underwritten by

